ADVM.OQ
Latest Trade
13.39USDChange
-0.03(-0.22%)Volume
272,926Today's Range
-
13.4652 Week Range
-
26.98As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 13.42 |
|---|---|
Open | 13.46 |
Volume | 272,926 |
3M AVG Volume | 20.90 |
Today's High | 13.46 |
Today's Low | 13.08 |
52 Week High | 26.98 |
52 Week Low | 7.36 |
Shares Out (MIL) | 97.48 |
Market Cap (MIL) | 1,305.23 |
Forward P/E | -10.24 |
Dividend (Yield %) | -- |
Adverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME, Provides 2021 Business Outlook
Adverum Biotechnologies Says Q3 Loss Per Share $0.31
Adverum Biotechnologies Announces $200 Million Public Offering Of Common Stock
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. The Company is evaluating its gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. It has collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products (AVA-311) for ophthalmic diseases. The Company develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its capabilities include clinical development, vector discovery, and in-house manufacturing, specifically in process development, assay development and current Good Manufacturing Practices (cGMP) quality control.
Industry
Biotechnology & Drugs
Executive Leadership
Patrick Machado
Independent Chairman of the Board
Leone D. Patterson
President
Laurent Fischer
Chief Executive Officer, Director
Thomas Leung
Chief Financial Officer
Angela Thedinga
Chief Technology Officer
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | -- |
Price To Book (MRQ) | 2.81 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -29.09 |
Return on Equity (TTM) | -27.70 |
* ADVERUM BIOTECHNOLOGIES ANNOUNCES NEW INFINITY PHASE 2 TRIAL FOR ADVM-022 IN DIABETIC MACULAR EDEMA, REPORTS RECENT BUSINESS PROGRESS AND FIRST QUARTER 2020 FINANCIAL RESULTS
* ADVERUM BIOTECHNOLOGIES REPORTS POSITIVE INTERIM DATA FROM COHORTS 1-3 OF OPTIC PHASE 1 TRIAL OF ADVM-022 INTRAVITREAL GENE THERAPY FOR WET AMD
* ADVERUM BIOTECHNOLOGIES DOSES FIRST PATIENT IN COHORT 4 OF OPTIC PHASE 1 CLINICAL TRIAL OF ADVM-022 INTRAVITREAL GENE THERAPY FOR WET AMD Source text for Eikon: Further company coverage:
* ADVERUM BIOTECHNOLOGIES INC - ON APRIL 16, INCREASED SIZE OF BOARD TO TEN MEMBERS Source text: [https://bit.ly/2wSTG7V] Further company coverage: (Reuters.Briefs@thomsonreuters.com)
* ADVERUM BIOTECHNOLOGIES REPORTS RECENT BUSINESS PROGRESS AND FOURTH QUARTER 2019 FINANCIAL RESULTS
* ADVERUM BIOTECHNOLOGIES ANNOUNCES $100 MILLION PUBLIC OFFERING OF COMMON STOCK
* ADVERUM BIOTECHNOLOGIES REPORTS NEW INTERIM DATA FROM COHORTS 1 AND 2 OF OPTIC PHASE 1 TRIAL OF ADVM-022 INTRAVITREAL GENE THERAPY FOR WET AMD AT ANGIOGENESIS, EXUDATION, AND DEGENERATION 2020
* ADVERUM BIOTECHNOLOGIES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
* BOARD AND AMBER SALZMAN, CHIEF EXECUTIVE OFFICER MADE A MUTUAL DETERMINATION THAT SALZMAN STEP DOWN
* ADVERUM BIOTECHNOLOGIES ANNOUNCES LONG-TERM PRECLINICAL EFFICACY DATA ON ADVM-022 GENE THERAPY IN WET AMD
* ADVERUM BIOTECHNOLOGIES REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
* ADVERUM BIOTECHNOLOGIES ANNOUNCES PRICING OF $60 MILLION PUBLIC OFFERING OF COMMON STOCK
* ADVERUM BIOTECHNOLOGIES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
* ANNOUNCES EXTENSION OF ITS COLLABORATION AGREEMENT WITH EDITAS MEDICINE INC
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.